NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH)

BZ NOTE: ClinicalTrials.gov information: http://www.clinicaltrials.gov/ct2/show/NCT02204579?term=NPSP795&rank=1

FULL PRESS RELEASE:

NPS Pharmaceuticals, Inc. NPSP, a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, has initiated a Phase 2a study to evaluate the safety and tolerability of NPSP795 in adult patients with Autosomal Dominant Hypocalcemia (ADH), an ultra-rare genetic disorder of calcium homeostasis. ADH is caused by mutations of the calcium-sensing receptor (CaSR) gene that increase the sensitivity of the receptor to serum calcium. NPSP795 is a selective calcium receptor antagonist, which binds to the CaSR and decreases its sensitivity to serum calcium. It’s mechanism of action is believed to restore the normal physiological action of the CaSR and address the underlying molecular defect in ADH to return to normal calcium homeostasis. The company expects to report preliminary top-line data from the study in late 2014 or early 2015.

“NPS Pharma is committed to advancing the understanding of Autosomal Dominant Hypocalcemia (ADH), an ultra-rare genetic disease that can lead to serious renal complications,” said Roger Garceau, MD, FAAP, executive vice president and chief medical officer of NPS Pharma. “This new study is an important step in our exploration of the potential of NPSP795 for the treatment of patients with ADH, who do not have approved treatment options."